LIXTE Biotechnology Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2015

A summary of common stock warrant activity during the six months ended June 30, 2015, including warrants to purchase common stock that were issued in conjunction with the Companys private placements, is presented below. For presentation purposes, warrants that were extended are considered as outstanding for the entire period in which such extension occurs.

						Weighted Average
	Number of			Weighted Average		Remaining Contractual
	Shares			Exercise Price		Life (in Years)

Warrants outstanding at December 31, 2014		2,928,800		$	0.592
Issued
Exercised		(1,050,000	)		0.300
Expired		(1,878,800	)		0.294
Warrants outstanding at June 30, 2015				$

Warrants exercisable at December 31, 2014		2,807,840		$	0.596
Warrants exercisable at June 30, 2015				$

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details